SUBCUTANEOUS DOSING OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	WANG, HONG, BENDER, BRENDAN CHRISTIAN, HOSSEINI, IRAJ, LI, CHIUNG, O'HEAR, CAROL ELAINE
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY METALLURGY ORGANIC CHEMISTRY PEPTIDES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of an anti-CD20/anti-CD3 bispecific antibody. La présente invention concerne le traitement de sujets ayant des troubles prolifératifs cellulaires positifs à CD20 (par ex., des troubles prolifératifs des lymphocytes B, tels que les lymphomes non hodgkiniens). Plus spécifiquement, l'invention concerne le traitement de sujets ayant un trouble prolifératif des lymphocytes B par administration sous-cutanée d'un anticorps bispécifique anti-CD20/anti-CD3.